×
About 178 results

ALLMedicine™ Pediatric Neuroblastoma Center

Research & Reviews  56 results

Lipid emulsion-induced hypertension post resection of pediatric neuroblastoma: a case r...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036777
BMC Pediatrics; Yuan L, Li T et. al.

Apr 27th, 2022 - Parenteral Nutrition (PN) is preferred when patient is unable to eat. Most clinically widely used lipid emulsion is now attracting more attention in its stability and adverse reactions. We report here the first case of lipid emulsions caused hyper...

CT-based morphologic and radiomics features for the classification of MYCN gene amplifi...
https://doi.org/10.1007/s00381-022-05534-3 10.1148/rg.2018170132 10.3322/caac.21654 10.1002/pbc.27556 10.1002/pbc.27363 10.1200/JCO.2008.16.6785 10.1200/jco.2011.29.18_suppl.2 10.1016/S1470-2045(05)70291-6 10.1016/j.jpedsurg.2018.12.023 10.1016/j.jpedsurg.2018.04.012 10.1016/j.jpedsurg.2012.03.040 10.1002/pbc.28153 10.1158/0008-5472.CAN-17-0339 10.1148/radiol.2015151169 10.7150/thno.30309 10.1007/s00261-019-02028-w 10.1056/NEJMoa1113205 10.1038/sj.bjc.6605014 10.18637/jss.v028.i05 10.1200/JCO.2008.16.6876 10.1002/pbc.26605 10.1148/radiol.11101352 10.1016/j.mri.2012.05.001 10.1148/radiol.2020191145 10.1093/bioinformatics/btt383 10.1111/rssb.12377 10.1007/s12021-010-9074-x 10.21105/joss.00786 10.1016/j.ijmedinf.2020.104313 10.3389/fonc.2021.687884 10.1007/s00330-020-07246-1 10.1002/pbc.29110 10.3389/fonc.2020.624079 10.1016/j.ijrobp.2018.05.053 10.1080/0284186X.2018.1445283 10.1186/s40644-019-0276-7 10.1038/s41598-018-36938-4 10.1038/s41416-020-0740-y 10.1016/j.compbiomed.2021.104752 10.1007/s00234-020-02403-1 10.1371/journal.pone.0217785 10.1016/j.ejca.2020.04.007 10.1002/pbc.28794 10.1038/nature12477
Child's Nervous System : ChNS : Official Journal of the I... Tan E, Merchant K et. al.

Apr 24th, 2022 - MYCN onco-gene amplification in neuroblastoma confers patients to the high-risk disease category for which prognosis is poor and more aggressive multimodal treatment is indicated. This retrospective study leverages machine learning techniques to d...

A hypothalamic pathway for Augmentor α-controlled body weight regulation.
https://doi.org/10.1073/pnas.2200476119
Proceedings of the National Academy of Sciences of the Un... Ahmed M, Kaur N et. al.

Apr 13th, 2022 - SignificanceThe receptor tyrosine kinase Alk was originally discovered as an oncogenic fusion protein generated in anaplastic large cell lymphoma. A variety of oncogenic Alk fusion proteins were subsequently identified as key drivers of subsets of...

The Diagnostic Value of 18F-FDG PET/CT Bone Marrow Uptake Pattern in Detecting Bone Mar...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758298
Contrast Media & Molecular Imaging; Liu J, Li C et. al.

Jan 28th, 2022 - To explore the diagnostic value of 18F-FDG PET/CT bone marrow uptake pattern (BMUP) in detecting bone marrow involvement (BMI) in pediatric neuroblastoma (NB) patients. Ninety-eight NB patients were enrolled in BMI analysis. Four patterns of bone ...

see more →

Clinicaltrials.gov  3 results

Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma
https://clinicaltrials.gov/ct2/show/NCT05027386

Aug 31st, 2021 - The enrolled patients diagnosed with recurrent or refractory pediatric neuroblastoma received apatinib combined with IT regimen chemotherapy, the treatment including combination therapy phase and monotherapy maintenance phase.

Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma
https://clinicaltrials.gov/ct2/show/NCT01404702

Dec 2nd, 2014 - Neuroblastoma (NB) is the most common extracranial solid tumor in children, with an annual incidence of 10.5 per million children less than 15 years of age. NB accounts for 15% of childhood cancer deaths. High risk (HR) patients carry a poor progn...

ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma
https://clinicaltrials.gov/ct2/show/NCT00533169

Dec 15th, 2011 - The Study Drugs: ZD6474 is a drug that slows down the function of proteins in tumor cells called protein tyrosine kinases. Tyrosine kinases normally cause tumor cells to grow. It is thought to have anti-cancer effects when given with or without ot...

see more →

News  12 results

Activating the Immune System Could be Key to Treating Pediatric Neuroblastoma
https://www.onclive.com/view/activating-the-immune-system-could-be-key-to-treating-pediatric-neuroblastoma

Mar 10th, 2022 - Chemoimmunotherapy is still a relatively new strategy for patients with pediatric neuroblastoma. Wayne Furman, MD, hopes that the humanized anti-disialoganglioside (anti-GD2) monoclonal antibody hu14.18K322A provides a breakthrough for children wi...

Rare Cancers Report: Pediatric Neuroblastoma
https://www.onclive.com/view/rare-cancers-report-pediatric-neuroblastoma

Feb 3rd, 2022 - Welcome to OncLiveOn Air®! I’m your host today, Jessica Hergert. OncLiveOn Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and p...

Yale Cancer Center Researchers Show Receptor Structure Reveals New Targets for Cancer Treatment
https://www.onclive.com/view/yale-cancer-center-researchers-show-receptor-structure-reveals-new-targets-for-cancer-treatment

Dec 10th, 2021 - A molecule known as anaplastic lymphoma kinase (ALK) is a driver of several cancers, including pediatric neuroblastoma, B-cell lymphomas, and myofibroblast tumors. But for years much about this molecule — its role in the body, which molecules inte...

Novel Chemoimmunotherapy Regimen Wows in Pediatric Neuroblastoma
https://www.medpagetoday.com/hematologyoncology/othercancers/96035

Dec 6th, 2021 - Adding a novel anti-GD2 antibody (hu14.18K322A) to induction chemotherapy for children with newly diagnosed high-risk neuroblastoma yielded impressive survival outcomes and improved early responses versus historical benchmarks, investigators repor...

Persistent Development of WEE1 Pathway Inhibitors Begins to Pay Off
https://www.onclive.com/view/persistent-development-of-wee1-pathway-inhibitors-begins-to-pay-off

Aug 25th, 2021 - WEE1 is a key regulator of the cell cycle that has been a target of cancer drug discovery efforts for more than a decade. The lead novel candidate, the WEE1 inhibitor adavosertib (AZD1775), has been tested in more than 50 completed or ongoing clin...

see more →